AZNCF News and Press, AstraZeneca Plc From 10/29/20

Compass Therapeutics has filed to raise $50 million in an IPO. The firm is advancing programs to treat various cancers, including Her2+ breast cancer. CMPX has produced intriguing results in preclinical studies for its lead candidate. For further details see: Compass The...

Foghorn Therapeutics has filed to raise $120 million in a U.S. IPO. The firm is developing treatments for ocular cancer and other cancers. FHTX is still at a preclinical stage of development, so the IPO may be more suited to long-term hold institutional investors. For furthe...

As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...

Healthcare REITs - which have been "ground-zero" of the coronavirus pandemic - have shown signs of life over the past quarter on stabilizing fundamentals and on hopes of a potential vaccine. For senior housing REITs, in particular, the pandemic has put a significant dent in near-term ...

Vaccine programs are progressing but it's still too early to know if they will be successful. Leading candidate vaccines from Pfizer/BioNTech, Moderna, Astra Zeneca/Oxford University and Inovio will not be ready for evaluation before the US election. Meantime with northern hemisph...

Andaz is an Australia-based performance-oriented specialist investment manager managing only one equity strategy. Yizhong Chan is the Founder and Executive Chairman and also serves as the portfolio manager for all. Our approach is to be highly selective and systematic in selecting onl...

Shattuck Labs has filed terms for its U.S. IPO. The firm is advancing a pipeline of treatment candidates for ovarian and other cancers. STTK has produced impressive results in early trials, has a significant collaboration with Takeda Pharmaceuticals and the IPO appears reasonably ...

U.S. equity markets snapped a four-week losing streak on a frenetic week of economic data and political developments that culminated with the hospitalization of the President of the United States. Throwing yet another curveball into the home stretch of a highly contentious U.S. electi...

Shattuck Labs has filed to raise development capital in a U.S. IPO. The firm is advancing drug treatment candidates for various cancer conditions. STTK has shown promising early trial results and has a strong collaboration partner in Takeda Pharmaceuticals. For further detai...

PFE/BNTX have increased enrolment in their late-stage study of BNT162b2, leading many to speculate as to why. MRNA has not increased enrolment but slowed enrolment to focus on diversity. AZN has fallen behind a little in the US. For further details see: COVID-19 Vaccine ...